<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Lipids Health Dis</journal-id><journal-id journal-id-type="iso-abbrev">Lipids Health Dis</journal-id><journal-id journal-id-type="pmc-domain-id">116</journal-id><journal-id journal-id-type="pmc-domain">liphdis</journal-id><journal-title-group><journal-title>Lipids in Health and Disease</journal-title></journal-title-group><issn pub-type="epub">1476-511X</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11223358</article-id><article-id pub-id-type="pmcid-ver">PMC11223358.1</article-id><article-id pub-id-type="pmcaid">11223358</article-id><article-id pub-id-type="pmcaiid">11223358</article-id><article-id pub-id-type="pmid">38965560</article-id><article-id pub-id-type="doi">10.1186/s12944-024-02200-2</article-id><article-id pub-id-type="publisher-id">2200</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Association between Parkinson&#8217;s disease and cardiovascular disease mortality: a prospective population-based study from NHANES</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Ke</surname><given-names initials="L">Li</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhao</surname><given-names initials="L">Lei</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Xing</surname><given-names initials="W">Wenli</given-names></name><address><email>19911866140@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tang</surname><given-names initials="Q">Qiaosheng</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label>Department of Neurology, Suining Central Hospital, Suining, Sichuan Province China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00zjgt856</institution-id><institution-id institution-id-type="GRID">grid.464371.3</institution-id><institution>Department of Neurology, </institution><institution>Nanxishan Hospital, </institution></institution-wrap>Nanning, Guangxi Zhuang Autonomous Region China </aff></contrib-group><pub-date pub-type="epub"><day>4</day><month>7</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>23</volume><issue-id pub-id-type="pmc-issue-id">452319</issue-id><elocation-id>212</elocation-id><history><date date-type="received"><day>9</day><month>5</month><year>2024</year></date><date date-type="accepted"><day>27</day><month>6</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>04</day><month>07</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>04</day><month>07</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-07-06 11:25:15.560"><day>06</day><month>07</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2024</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12944_2024_Article_2200.pdf"/><abstract id="Abs1"><sec><title>Background and aim</title><p id="Par1">Conflicting results have been reported on the association between Parkinson's disease (PD) and cardiovascular disease (CVD) mortality in different populations. Therefore, studying the relationship between PD and CVD mortality is crucial to reduce mortality caused by the former.</p></sec><sec><title>Methods</title><p id="Par2">In this cohort investigation, we enrolled 28,242 participants from the National Health and Nutrition Examination Survey spanning from 2003 to 2018. The 380 cases of PD in the cohort were identified by documenting &#8216;ANTIPARKINSON AGENTS&#8217; in their reported prescription medications. Mortality outcomes were ascertained by cross-referencing the cohort database with the National Death Index, which was last updated on 31 December 2019. Cardiovascular disease mortality was categorised according to the 10th revision of the International Classification of Diseases by using a spectrum of diagnostic codes. Weighted multivariable Cox regression analysis was used to examine the association between PD and the risk of CVD mortality.</p></sec><sec><title>Results</title><p id="Par3">A total of 28,242 adults were included in the study [mean age, 60.156 (12.55) years, 13,766 men (48.74%)], and the median follow-up period was 89 months. Individuals with PD had an adjusted HR of 1.82 (95% CI, 1.24&#8211;2.69; <italic toggle="yes">p</italic>&#8201;=&#8201;0.002) for CVD mortality and 1.84 (95% CI, 1.44&#8211;2.33; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) for all-cause mortality compared with those without PD. The association between PD and CVD mortality was robust in sensitivity analyses, after excluding participants who died within 2&#8201;years of follow-up and those with a history of cancer at baseline [HR,1.82 (95% CI, 1.20&#8211;2.75; <italic toggle="yes">p</italic>&#8201;=&#8201;0.005)].</p></sec><sec><title>Conclusions</title><p id="Par4">PD was associated with a high long-term CVD mortality rate in the US population.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>NHANES</kwd><kwd>Cardiovascular disease mortality</kwd><kwd>Parkinson&#8217;s disease</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Parkinson&#8217;s disease (PD) is a sophisticated and progressively worsening neurodegenerative condition and characterised by degeneration of dopaminergic neurons in the substantia nigra and accumulation of alpha synuclein in neurons; PD includes motor symptoms, such as tremor, muscle stiffness, reduced mobility and balance, and non-motor features such as cognitive decline, depression and pain [<xref ref-type="bibr" rid="CR1">1</xref>]. Although PD is relatively rare in individuals under the age of 50 years, the prevalence and burden of PD increase rapidly worldwide as life expectancy increases. The 2019 Global Burden of Disease, Injury and Risk Factors (GBD) study estimated that more than 8.5 million people worldwide suffer from PD [<xref ref-type="bibr" rid="CR2">2</xref>]. The global burden of PD is expected to exceed 17 million cases by 2040 [<xref ref-type="bibr" rid="CR3">3</xref>]. Therefore, evaluating serious complications that are caused and actively intervened by PD is crucial to reduce the disability and mortality rates of PD.</p><p id="Par6">Although epidemiologic studies have consistently reported that PD is associated with higher premature mortality rates than the general population [<xref ref-type="bibr" rid="CR4">4</xref>], the association between PD and cardiovascular diseases (CVDs) remains uncertain. Previous studies suggested that the incidence of CVD is reduced in people with PD [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>], and a lack of dopamine may prevent ischaemic damage to the brain by reducing the effects of excitatory toxicity. However, patients with PD have a higher risk of MI, ischaemic stroke, CHF and all-cause mortality than those without PD [<xref ref-type="bibr" rid="CR7">7</xref>]. In the United States, CVDs including myocardial infarction (MI), ischaemic stroke and congestive heart failure (CHF) account for more than 25% of deaths [<xref ref-type="bibr" rid="CR8">8</xref>]. Therefore, exploring the relationship between PD and CVD mortality among adult Americans is important.</p><p id="Par7">In this study, we utilised a substantial cohort with extensive, long-term follow-up data from the National Health and Nutrition Examination Survey (NHANES) to evaluate CVD mortality rates and overall mortality rates among individuals with PD.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study population</title><p id="Par8">From 2003 to 2018, 80,312 participants were involved in the NHANES study. Participants under 40&#160;years of age were excluded based on the epidemiological characteristics of PD. After removing participants with missing data on PD and loss to follow-up, statistical analysis was performed on 28,242 participants, which included 380 participants with PD and 27,862 participants without PD. The complete process of data integration is illustrated in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>Study flow chart</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="12944_2024_2200_Fig1_HTML.jpg"/></fig></p><p id="Par9">The National Centre for Health Statistics (NCHS) conducts NHANES, a national representative study, to evaluate the health or nutritional state of the US population that is not institutionalised. Utilising a multistage, stratified probability sampling strategy, NHANES collects demographic and detailed health information through home visits, screening, and laboratory testing, by a mobile exam centre. The NCHS Research Ethics Review Board approved the NHANES study protocol, and participants provided written informed permission at enrolment (source: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/nchs/nhanes/irba98.htm">https://www.cdc.gov/nchs/nhanes/irba98.htm</ext-link>). The Suining Central Hospital institutional review board deemed the study exempt due to its utilisation of publicly accessible and deidentified data, thus waiving the requirement for informed consent. This study adhered to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines to maintain high-quality reporting.</p></sec><sec id="Sec4"><title>Assessment of PD and mortality</title><p id="Par10">In the NHANES database, participants with PD were identified by the presence of &#8216;ANTIPARKINSON AGENTS&#8217; in their prescription medication responses [<xref ref-type="bibr" rid="CR9">9</xref>&#8211;<xref ref-type="bibr" rid="CR11">11</xref>]. Individuals had to be receiving treatment for PD to be classified as having the disease due to limitations in NHANES medications and codes. Others were categorised as non-Parkinson&#8217;s disease participants. Mortality data were collected by linking the cohort database to the Centres for Disease Control&#8217;s National Death Index as of 31 December 2019. Cardiovascular mortality in this analysis encompasses a range of ICD codes, specifically: I00&#8211;I09 for acute rheumatic fever and chronic rheumatic heart conditions; I11 for hypertensive heart disease; I13 for combined hypertensive heart and renal disease; I20&#8211;I25 for ischemic heart diseases; I26&#8211;I28 for pulmonary embolism and other acute pulmonary heart conditions; I29 for a variety of CVDs due to diverse causes; I30&#8211;I51 for additional forms of heart disease; and I60&#8211;I69 for cerebrovascular disorders.</p></sec><sec id="Sec5"><title>Assessment of covariables</title><p id="Par11">Potential covariables included age, gender, marital status, race/ethnicity, education level, family income, body mass index (BMI), smoking status, alcohol drinking status, diabetes and hypertension [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Race/ethnicity was classified as non-Hispanic white, non-Hispanic black, Mexican American or others. Marital status was defined as married, living with a partner or living alone. Educational attainment was divided into three categories: fewer than nine years, nine to 12&#160;years and more than 12&#160;years. According to a US government report, family income was divided into three categories based on the poverty income ratio (PIR): low (PIR&#8201;&#8804;&#8201;1.3), medium (PIR&#8201;&gt;&#8201;1.3 to 3.5) and high (PIR&#8201;&gt;&#8201;3.5). Smoking status was classified as &#8216;never&#8217; (smoked fewer than 100 cigarettes), &#8216;former&#8217; (smoked more than 100 cigarettes in life and smoke not at all now) and &#8216;now&#8217; (smoked moth than 100 cigarettes in life and smoke some days or every day). The classification of alcohol consumption included the categories of &#8216;never&#8217; (having never consumed alcohol in their lifetime), &#8216;former&#8217; (having previously consumed alcohol but no longer do), &#8216;heavy&#8217; alcohol use (&#8805;&#8201;3 drinks daily for women,&#8201;&#8805;&#8201;4 drinks daily for men, or binge drinking [&#8805;&#8201;4 drinks in one occasion for women,&#8201;&#8805;&#8201;5 drinks in one occasion for men] on 5 or more days in a month), &#8216;moderate&#8217; alcohol use (&#8805;&#8201;2 drinks daily for women,&#8201;&#8805;&#8201;3 drinks daily for men, or binge drinking on&#8201;&#8805;&#8201;2&#160;days in a month, or a history of daily binge drinking) and &#8216;mild&#8217; alcohol use (not meeting the criteria mentioned above) [<xref ref-type="bibr" rid="CR13">13</xref>]. Physical activity (PA) was defined as the time individuals spent in engaging in activities such as walking, biking, household chores, work-related tasks, and recreational pursuits throughout the week; if exercise was not conducted in a week, then the exercise time was 0. Previous diseases, including hypertension, diabetes, stroke, and coronary heart disease, were identified through participants&#8217; responses to the questionnaire regarding whether a doctor had been notified of these conditions in the past.</p></sec><sec id="Sec6"><title>Statistical analysis</title><p id="Par12">This study conducted a secondary analysis of publicly available data from the NHANES dataset. Sampling weights and design variables were used in all analyses to avoid biased estimates and inflated significance levels. Therefore, our analysis followed the NHANES guidelines by incorporating a complex sampling design and sampling weights [<xref ref-type="bibr" rid="CR14">14</xref>]. Our research data were derived from family interviews and Mobile Examination Centre (MEC) data collected during NHANES surveys. As per the NHANES survey sample weight analysis guidelines, weights provided by MEC should be utilised. Sampling weight was calculated by taking the MEC weight for each participant and multiplying it by 1/8&#8201;&#215;&#8201;2&#160;years, spanning from 2003 to 2018. The National Death Index is updated every 4&#160;years, and the latest follow-up data are currently available as of 31 December 2019. The follow-up period for each participant was calculated from the date of testing at the MEC to the date of death or the end of follow-up on 31 December 2019. Considering the small percentage of missing data for all variables (missing rates ranged from 0 to 9%), we employed a multivariable single imputation method using an iterative imputer with a Bayesian Ridge model as the estimator at each imputation step, following the approach proposed by van Buuren and Groothuis&#8211;Oudshoorn (2011). Categorical and continuous variables were presented as unweighted percentages and means (standard deviation [SD]). The study utilised linear regression analyses and Chi-square tests to compare continuous and categorical variables, respectively. Weighted multivariable Cox proportional hazards regression models were employed to assess the hazard ratio (HR) and 95% confidence interval (95% CI) for the relationship between PD and the risks of CVD and all-cause mortality. Model 1 was adjusted for age, sex, marital status, race/ethnicity, education level, family income and NHANES cycle. Model 2 included additional adjustments for smoking status, alcohol drinking status and physical activity. Finally, Model 3 was further adjusted for BMI, diabetes and hypertension [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Sensitivity analyses were performed to assess the reliability of our findings. To mitigate the risk of reverse causality, we excluded individuals who passed away within 2 years of recruitment. Participants with cancer were also excluded to prevent any potential impact on mortality rate [<xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par13">To analyse the association between PD and CVD mortality based on general characteristics, subgroup analysis was conducted to analyse gender (male vs. female), age (&lt;&#8201;50&#160;years vs.&#8201;&#8805;&#8201;50&#160;years), race/ethnicity (non-Hispanic white vs. other), BMI (&lt;&#8201;30&#160;kg/m<sup>2</sup> vs.&#8201;&#8805;&#8201;30&#160;kg/m<sup>2</sup>), smoking status (never compared with before or now) and drinking status (never compared with before or now) by using a multivariable Cox proportional hazards regression model. PD is considered an age-related condition, with the incidence and prevalence rates increasing steadily with age. When PD occurs in individuals under the age of 50&#160;years, it is referred to as early-onset PD. Subgroup analysis often uses 50&#160;years old as the age threshold [<xref ref-type="bibr" rid="CR16">16</xref>]. Research indicated a link between being underweight and a higher likelihood of developing PD [<xref ref-type="bibr" rid="CR17">17</xref>]. Additionally, a clear negative correlation exists between BMI levels at the time of diagnosis and mortality rates among individuals with PD [<xref ref-type="bibr" rid="CR18">18</xref>]. Obesity, defined as having a BMI&#8201;&#8805;&#8201;30&#160;kg/m<sup>2</sup>, is associated with high mortality rates from heart disease and stroke [<xref ref-type="bibr" rid="CR19">19</xref>]. As a result, a BMI of 30&#160;kg/m<sup>2</sup> was utilised as the cut-off point for subgroup analysis. The covariates were adjusted in the same way as in Model 3. Likelihood ratio testing was used to investigate the interactions of the subgroups. All analyses were performed using statistical software packages R4.3.3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.R-project.org">http://www.R-project.org</ext-link>) and Free Statistics software version 1.9.2 (Beijing Free Clinical Medical Technology Co., Ltd.).</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>Baseline characteristics</title><p id="Par14">At baseline, 380 participants had PD, whereas 27,862 did not. Table <xref rid="Tab1" ref-type="table">1</xref> shows the baseline characteristics of the 28,242 study participants. The mean (SD) age of the participants was 60.1 (12.5) years, and 13,766 (48.7%) were men and 14,476 (51.2%) were women. In comparison with the 27,862 individuals without PD, the 380 individuals with PD were more likely to be older ( 60.092(12.539) years vs 64.829 (12.955) years respectively), have a higher BMI (30.566 (7.422) kg/m<sup>2</sup> vs. 29.382 (6.666), respectively) and they were more likely to have a higher prevalence rate of diabetes (17,090.00 (25.47%) vs.128.00 (33.68%), respectively) and hypertension [15736.00 (56.49%) vs. 259.00 (68.16%), respectively].
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>Baseline characteristics of participants in the NHANES 2003&#8211;2018 cycles</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3" colspan="1">Characteristic</th><th align="left" colspan="5" rowspan="1">Participants<sup>a</sup></th></tr><tr><th align="left" colspan="1" rowspan="1">Overall</th><th align="left" colspan="1" rowspan="1">Non-PD</th><th align="left" colspan="1" rowspan="1">PD</th><th align="left" colspan="2" rowspan="1"><italic toggle="yes">p</italic></th></tr><tr><th align="left" colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#8201;=&#8201;28,242</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#8201;=&#8201;27,862</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#8201;=&#8201;380</th><th align="left" colspan="2" rowspan="1"/></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age</td><td align="left" colspan="1" rowspan="1">60.15 (12.55)</td><td align="left" colspan="1" rowspan="1">60.09 (12.53)</td><td align="left" colspan="1" rowspan="1">64.82 (12.95)</td><td align="left" colspan="2" rowspan="1">&#8201;&lt;&#8201;0.0001</td></tr><tr><td align="left" colspan="6" rowspan="1">Sex</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Male</td><td align="left" colspan="1" rowspan="1">13,766.00 (48.74)</td><td align="left" colspan="1" rowspan="1">13,589.00 (48.77)</td><td align="left" colspan="1" rowspan="1">177.00 (46.58)</td><td align="left" colspan="2" rowspan="1">0.3955</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Female</td><td align="left" colspan="1" rowspan="1">14,476.00 (51.26)</td><td align="left" colspan="1" rowspan="1">14,273.00 (51.23)</td><td align="left" colspan="1" rowspan="1">203.00 (53.42)</td><td align="left" colspan="2" rowspan="1"/></tr><tr><td align="left" colspan="6" rowspan="1">Race</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Non-Hispanic White</td><td align="left" colspan="1" rowspan="1">12,763.00 (45.19)</td><td align="left" colspan="1" rowspan="1">12,515.00 (44.92)</td><td align="left" colspan="1" rowspan="1">248.00 (65.26)</td><td align="left" colspan="2" rowspan="1">&#8201;&lt;&#8201;0.0001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Non-Hispanic Black</td><td align="left" colspan="1" rowspan="1">6107.00 (21.62)</td><td align="left" colspan="1" rowspan="1">6052.00 (21.72)</td><td align="left" colspan="1" rowspan="1">55.00 (14.47)</td><td align="left" colspan="2" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Mexican American</td><td align="left" colspan="1" rowspan="1">4163.00 (14.74)</td><td align="left" colspan="1" rowspan="1">4126.00 (14.81)</td><td align="left" colspan="1" rowspan="1">37.00 ( 9.74)</td><td align="left" colspan="2" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Oher</td><td align="left" colspan="1" rowspan="1">5209.00 (18.44)</td><td align="left" colspan="1" rowspan="1">5169.00 (18.55)</td><td align="left" colspan="1" rowspan="1">40.00 (10.53)</td><td align="left" colspan="2" rowspan="1"/></tr><tr><td align="left" colspan="6" rowspan="1">Marital</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Married or living with partners</td><td align="left" colspan="1" rowspan="1">17,361 (61.51)</td><td align="left" colspan="1" rowspan="1">17,164(61.64)</td><td align="left" colspan="1" rowspan="1">197.00 (51.84)</td><td align="left" colspan="2" rowspan="1">0.0001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Living alone</td><td align="left" colspan="1" rowspan="1">10,863.00 (38.49)</td><td align="left" colspan="1" rowspan="1">10,680 .00(38.36)</td><td align="left" colspan="1" rowspan="1">183.00(48.16)</td><td align="left" colspan="2" rowspan="1"/></tr><tr><td align="left" colspan="6" rowspan="1">PIR</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8201;&#8804;&#8201;1.30</td><td align="left" colspan="1" rowspan="1">7566.00 (29.50)</td><td align="left" colspan="1" rowspan="1">7432.00 (29.37)</td><td align="left" colspan="1" rowspan="1">134.00 (38.95)</td><td align="left" colspan="2" rowspan="1">&#8201;&lt;&#8201;0.0001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;1.31&#8211;3.50</td><td align="left" colspan="1" rowspan="1">9806.00 (38.24)</td><td align="left" colspan="1" rowspan="1">9670.00 (38.22)</td><td align="left" colspan="1" rowspan="1">136.00 (39.53)</td><td align="left" colspan="2" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8201;&gt;&#8201;3.50</td><td align="left" colspan="1" rowspan="1">8273.00 (32.26)</td><td align="left" colspan="1" rowspan="1">8199.00 (32.41)</td><td align="left" colspan="1" rowspan="1">74.00 (21.51)</td><td align="left" colspan="2" rowspan="1"/></tr><tr><td align="left" colspan="6" rowspan="1">Education</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Less than high school</td><td align="left" colspan="1" rowspan="1">8008.00 (28.40)</td><td align="left" colspan="1" rowspan="1">7883.00 (28.34)</td><td align="left" colspan="1" rowspan="1">125.00 (32.89)</td><td align="left" colspan="2" rowspan="1">0.1305</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;High school or equivalent</td><td align="left" colspan="1" rowspan="1">6555.00 (23.25)</td><td align="left" colspan="1" rowspan="1">6476.00 (23.28)</td><td align="left" colspan="1" rowspan="1">79.00 (20.79)</td><td align="left" colspan="2" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Above high school</td><td align="left" colspan="1" rowspan="1">13,635.00 (48.35)</td><td align="left" colspan="1" rowspan="1">13,459.00 (48.38)</td><td align="left" colspan="1" rowspan="1">176.00 (46.32)</td><td align="left" colspan="2" rowspan="1"/></tr><tr><td align="left" colspan="6" rowspan="1">Smoke</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Never</td><td align="left" colspan="1" rowspan="1">14,457.00 (51.23)</td><td align="left" colspan="1" rowspan="1">14,280.00 (51.29)</td><td align="left" colspan="1" rowspan="1">177.00 (46.70)</td><td align="left" colspan="2" rowspan="1">0.0809</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Former</td><td align="left" colspan="1" rowspan="1">8518.00 (30.18)</td><td align="left" colspan="1" rowspan="1">8402.00 (30.18)</td><td align="left" colspan="1" rowspan="1">116.00 (30.61)</td><td align="left" colspan="2" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Now</td><td align="left" colspan="1" rowspan="1">5247.00 (18.59)</td><td align="left" colspan="1" rowspan="1">5161.00 (18.54)</td><td align="left" colspan="1" rowspan="1">86.00 (22.69)</td><td align="left" colspan="2" rowspan="1"/></tr><tr><td align="left" colspan="6" rowspan="1">Alcohol</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Never</td><td align="left" colspan="1" rowspan="1">3850.00 (15.47)</td><td align="left" colspan="1" rowspan="1">3802.00 (15.48)</td><td align="left" colspan="1" rowspan="1">48.00 (15.00)</td><td align="left" colspan="2" rowspan="1">&#8201;&lt;&#8201;0.0001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Former</td><td align="left" colspan="1" rowspan="1">5422.00 (21.79)</td><td align="left" colspan="1" rowspan="1">5319.00 (21.66)</td><td align="left" colspan="1" rowspan="1">103.00 (32.19)</td><td align="left" colspan="2" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Mild</td><td align="left" colspan="1" rowspan="1">8929.00 (35.89)</td><td align="left" colspan="1" rowspan="1">8814.00 (35.89)</td><td align="left" colspan="1" rowspan="1">115.00 (35.94)</td><td align="left" colspan="2" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Moderate</td><td align="left" colspan="1" rowspan="1">3257.00 (13.09)</td><td align="left" colspan="1" rowspan="1">3232.00 (13.16)</td><td align="left" colspan="1" rowspan="1">25.00 ( 7.81)</td><td align="left" colspan="2" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Heavy</td><td align="left" colspan="1" rowspan="1">3422.00 (13.75)</td><td align="left" colspan="1" rowspan="1">3393.00 (13.82)</td><td align="left" colspan="1" rowspan="1">29.00 ( 9.06)</td><td align="left" colspan="2" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Physical activity, min/week</td><td align="left" colspan="1" rowspan="1">583.95(1202.83)</td><td align="left" colspan="1" rowspan="1">587.54 (1206.58)</td><td align="left" colspan="1" rowspan="1">321.06(846.77)</td><td align="left" colspan="2" rowspan="1">&#8201;&lt;&#8201;0.0001</td></tr><tr><td align="left" colspan="1" rowspan="1">BMI/kg.m2</td><td align="left" colspan="1" rowspan="1">29.39 (6.67)</td><td align="left" colspan="1" rowspan="1">29.38(6.66)</td><td align="left" colspan="1" rowspan="1">30.56 (7.42)</td><td align="left" colspan="2" rowspan="1">0.0027</td></tr><tr><td align="left" colspan="6" rowspan="1">Hypertension</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;No</td><td align="left" colspan="1" rowspan="1">12,241.00 (43.35)</td><td align="left" colspan="1" rowspan="1">12,120.00 (43.51)</td><td align="left" colspan="1" rowspan="1">121.00 (31.84)</td><td align="left" colspan="2" rowspan="1">&#8201;&lt;&#8201;0.0001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Yes</td><td align="left" colspan="1" rowspan="1">15,995.00 (56.65)</td><td align="left" colspan="1" rowspan="1">15,736.00 (56.49)</td><td align="left" colspan="1" rowspan="1">259.00 (68.16)</td><td align="left" colspan="2" rowspan="1"/></tr><tr><td align="left" colspan="6" rowspan="1">Diabetes</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;No</td><td align="left" colspan="1" rowspan="1">21,001.00 (74.42)</td><td align="left" colspan="1" rowspan="1">20,749.00 (74.53)</td><td align="left" colspan="1" rowspan="1">252.00 (66.32)</td><td align="left" colspan="2" rowspan="1">0.0003</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Yes</td><td align="left" colspan="1" rowspan="1">7218.00 (25.58)</td><td align="left" colspan="1" rowspan="1">7090.00 (25.47)</td><td align="left" colspan="2" rowspan="1">128.00 (33.68)</td><td align="left" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">Abbreviation</italic>: <italic toggle="yes">NHANES</italic> National Health and Nutrition Examination Survey</p><p><sup>a</sup>Data are presented as unweighted number for categorical variables (percentage) and continuous variables (mean&#8201;&#177;&#8201;standard error)</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec9"><title>PD and mortality</title><p id="Par15">During 1&#8211;16&#160;years of follow-up of NHANES 2003&#8211;2018, a total of 5,268 all-cause deaths and 1.658 CVD deaths were identified. The median follow-up period was 89&#160;months. Individuals with PD had an adjusted HR of 1.82 (95% CI, 1.24&#8211;2.69; <italic toggle="yes">p</italic>&#8201;=&#8201;0.002) for CVD mortality and 1.84 (95% CI, 1.44&#8211;2.33; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) for all-cause mortality compared with those without PD (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). Figure&#160;<xref rid="Fig2" ref-type="fig">2</xref> displays the Kaplan&#8211;Meier curve for CVD mortality and the observed survival rates in the PD group compared with those in the non-PD group. Hence, the observed survival in the PD group was significantly lower than that in the non-PD population.
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>Hazard ratios of CVD and all-cause mortality by PD among adults in NHANES 2003&#8211;2018</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1"/><th align="left" colspan="4" rowspan="1">Deaths, no./total no</th></tr><tr><th align="left" colspan="1" rowspan="1">Without PD</th><th align="left" colspan="1" rowspan="1">With PD</th><th align="left" colspan="1" rowspan="1">HR (95% CI)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P_value</italic></th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1">All-cause mortality</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Crude model</td><td align="left" colspan="1" rowspan="1">5133/27862</td><td align="left" colspan="1" rowspan="1">135/380</td><td align="left" colspan="1" rowspan="1">2.44(1.84, 3.25)</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Mode 1</td><td align="left" colspan="1" rowspan="1">5133/27862</td><td align="left" colspan="1" rowspan="1">135/380</td><td align="left" colspan="1" rowspan="1">1.84(1.43, 2.37)</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Model 2</td><td align="left" colspan="1" rowspan="1">5133/27862</td><td align="left" colspan="1" rowspan="1">135/380</td><td align="left" colspan="1" rowspan="1">1.85(1.47, 2.33)</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Model 3</td><td align="left" colspan="1" rowspan="1">5133/27862</td><td align="left" colspan="1" rowspan="1">135/380</td><td align="left" colspan="1" rowspan="1">1.84(1.44, 2.33)</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">CVD mortality</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Crude model</td><td align="left" colspan="1" rowspan="1">1616/27862</td><td align="left" colspan="1" rowspan="1">42/380</td><td align="left" colspan="1" rowspan="1">2.44(1.97, 4.11)</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Mode 1</td><td align="left" colspan="1" rowspan="1">1616/27862</td><td align="left" colspan="1" rowspan="1">42/380</td><td align="left" colspan="1" rowspan="1">1.95(1.32, 2.89)</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Model 2</td><td align="left" colspan="1" rowspan="1">1616/27862</td><td align="left" colspan="1" rowspan="1">42/380</td><td align="left" colspan="1" rowspan="1">1.87(1.27, 2.73)</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Model 3</td><td align="left" colspan="1" rowspan="1">1616/27862</td><td align="left" colspan="1" rowspan="1">42/380</td><td align="left" colspan="1" rowspan="1">1.82(1.24, 2.69)</td><td align="left" colspan="1" rowspan="1">0.002</td></tr></tbody></table><table-wrap-foot><p>Model1: Adjusted for age, sex, marital status, race/ethnicity, education level, family income, and NHANES cycle</p><p>Model2: Further adjusted for smoking status, Physical activity and alcohol drinking status</p><p>Model3: Further adjusted for BMI, hypertension, diabetes</p></table-wrap-foot></table-wrap><fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>Kaplan&#8211;Meier survival curve for CVD mortality in people with and without PD</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="12944_2024_2200_Fig2_HTML.jpg"/></fig></p></sec><sec id="Sec10"><title>Subgroup analyses</title><p id="Par16">Figure&#160;<xref rid="Fig3" ref-type="fig">3</xref> presents the results of subgroup analyses. PD was associated with CVD mortality in participants who were aged&#8201;&#8805;&#8201;50&#160;years (HR, 1.96; 95% CI, 1.26&#8211;3.04), non-Hispanic White (HR, 1.96; 95% CI, 1.26&#8211;3.04), male (HR,3.10; 95% CI, 2.05&#8211;4.70), those with a BMI&#8201;&lt;&#8201;30&#160;kg/m2 (HR, 2.34; 95% CI, 1.41&#8211;3.87), never smoking (HR, 2.68; 95% CI, 1.66&#8211;4,33) and former or current alcohol drinkers (HR, 2.20; 95% CI, 1.47&#8211;3.29). PD was not associated with PD and CVD mortality in females, aged&#8201;&lt;&#8201;50&#160;years, other races/ethnicities, those with a BMI&#8201;&#8805;&#8201;30&#160;kg/m2, former or current smokers and never drinkers.<fig id="Fig3" position="float" orientation="portrait"><label>Fig.&#160;3</label><caption><p>Association between Parkinson's disease and CVD mortality according to general characteristics. The stratifications were adjusted for all variables (education level, marital status, family income, NHANES cycle, physical activity, hypertension and diabetes except for the stratification factor itself. Squares represent the HRs and horizontal lines represent 95% CIs. Diamonds represent the overall HR, and the outer points of the diamonds represent the 95% CI. BMI, body mass index; CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="12944_2024_2200_Fig3_HTML.jpg"/></fig></p></sec><sec id="Sec11"><title>Sensitivity analysis</title><p id="Par17">The results of sensitivity analyses are presented in Table&#160;<xref rid="Tab3" ref-type="table">3</xref>. After excluding participants who died within 2&#160;years of follow-up and those with a history of cancer at baseline, the adjusted Hazard Ratio (HR) for CVD mortality was 1.82 (95% CI, 1.20&#8211;2.75; <italic toggle="yes">p</italic>&#8201;=&#8201;0.005) and the all-cause mortality was 1.77 (95% CI, 1.38&#8211;2.26; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) for individuals with Parkinson's Disease (PD) compared with those without PD.
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table&#160;3</label><caption><p>Sensitivity analyses, excluding those with cancer and died within 2&#160;years of follow-up</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1"/><th align="left" colspan="4" rowspan="1">Deaths, no./total no</th></tr><tr><th align="left" colspan="1" rowspan="1">Without PD</th><th align="left" colspan="1" rowspan="1">With PD</th><th align="left" colspan="1" rowspan="1">HR (95% CI)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P_value</italic></th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1">All-cause mortality</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Crude model</td><td align="left" colspan="1" rowspan="1">3273/22705</td><td align="left" colspan="1" rowspan="1">82/273</td><td align="left" colspan="1" rowspan="1">2.44(1.84, 3.25)</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Mode 1</td><td align="left" colspan="1" rowspan="1">3273/22705</td><td align="left" colspan="1" rowspan="1">82/273</td><td align="left" colspan="1" rowspan="1">1.84(1.43, 2.37)</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Model 2</td><td align="left" colspan="1" rowspan="1">3273/22705</td><td align="left" colspan="1" rowspan="1">82/273</td><td align="left" colspan="1" rowspan="1">1.73(1.36, 2.20)</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Model 3</td><td align="left" colspan="1" rowspan="1">3273/22705</td><td align="left" colspan="1" rowspan="1">82/273</td><td align="left" colspan="1" rowspan="1">1.77(1.38, 2.26)</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">CVD mortality</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Crude model</td><td align="left" colspan="1" rowspan="1">1069/22705</td><td align="left" colspan="1" rowspan="1">30/273</td><td align="left" colspan="1" rowspan="1">2.71(1.80, 4.08)</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Mode 1</td><td align="left" colspan="1" rowspan="1">1069/22705</td><td align="left" colspan="1" rowspan="1">30/273</td><td align="left" colspan="1" rowspan="1">1.91(1.23, 2.95)</td><td align="left" colspan="1" rowspan="1">0.004</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Model 2</td><td align="left" colspan="1" rowspan="1">1069/22705</td><td align="left" colspan="1" rowspan="1">30/273</td><td align="left" colspan="1" rowspan="1">1.77(1.17, 2.68)</td><td align="left" colspan="1" rowspan="1">0.007</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Model 3</td><td align="left" colspan="1" rowspan="1">1069/22705</td><td align="left" colspan="1" rowspan="1">30/273</td><td align="left" colspan="1" rowspan="1">1.82(1.20, 2.75)</td><td align="left" colspan="1" rowspan="1">0.005</td></tr></tbody></table><table-wrap-foot><p>Model1: Adjusted for age, sex, marital status, race/ethnicity, education level, family income, and NHANES cycle</p><p>Model2: Further adjusted for smoking status, Physical activity and alcohol drinking status</p><p>Model3: Further adjusted for BMI, hypertension, diabetes</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec12"><title>Discussion</title><p id="Par18">This cohort study's findings indicate that PD elevates the risk of CVD mortality and overall mortality. The robustness of these results was confirmed through subgroup and sensitivity analyses.</p><p id="Par19">Our findings on overall mortality rate are consistent with previous research findings. A historical cohort study spanning 11 years revealed a mortality rate of 1.64 (95% CI: 1.21&#8211;2.23) among patients with PD compared with the control group [<xref ref-type="bibr" rid="CR20">20</xref>]. Similarly, the Sydney and Netherlands multicentre study reported a higher mortality rate in individuals with PK compared to population data [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. A meta-analysis concluded that cognitive impairment/dementia, ageing, late age of onset, male and gait disturbance are risk factors for mortality in patients with PD [<xref ref-type="bibr" rid="CR23">23</xref>].</p><p id="Par20">Research on CVD mortality in people with PD remains limited and controversial. A previous study showed that the risk of ischemic heart disease in patients with PD remains unchanged compared with that in the general population (HR 1.1, 95% CI 0.62.0) [<xref ref-type="bibr" rid="CR24">24</xref>]. Even some studies suggested that people with PD have a reduced overall incidence of ischaemic stroke and heart attack [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. Individuals with PD may encounter autonomic dysfunction, cardiomyopathy, coronary heart disease, arrhythmia or sudden cardiac death (SCD), resulting in a high prevalence of heart failure [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. In a recent study by Park et al. [<xref ref-type="bibr" rid="CR11">11</xref>]. in South Korea, a nationwide cohort analysis revealed that individuals with PD may face a greater probability of experiencing cardiovascular events and death compared with those without the condition; individuals with PD had a higher risk of myocardial infarction (HR 1.43,95% CI:1.28&#8211;1.59), ischemic stroke (HR 1.42,95% CI:1.31&#8211;1.54]) and congestive heart failure (HR 1.65,95% CI:1.52&#8211;1.78). Our research findings also indicate that the CVD mortality rate among patients with PD is higher than those in non-Parkinson&#8217;s patients. By utilising a substantial sample size of American participants, our study contributes to enhancing the overall applicability of the results.</p><p id="Par21">Autonomic dysfunction is frequently observed in PD and can manifest in the autonomic nervous system, including the heart [<xref ref-type="bibr" rid="CR29">29</xref>]. In a study conducted on the heart tissue of Parkinson's disease patients in Japan, it was discovered that 9 out of 11 patients had Lewy bodies present in tyrosine hydroxylase positive and negative neural processes, suggesting that the postganglionic sympathetic nervous system and intrinsic neurons in the heart play a role in the development of PD [<xref ref-type="bibr" rid="CR30">30</xref>]. A prospective study conducted in Sweden revealed that diabetes and elevated fasting blood glucose levels were identified as risk factors for PD. The study also found that a higher neutrophil to lymphocyte ratio (NLR) in the general population was linked to an increased risk of PD. Interestingly, diabetes, fasting glucose and NLR are all associated with the risk of coronary events or ischemic stroke [<xref ref-type="bibr" rid="CR12">12</xref>]. Hence, patients with PD can develop coronary heart disease and ischemic stroke. Most patients with PD receive levodopa treatment, which has been shown to increase homocysteine levels in the blood; elevated homocysteine levels have been associated with a higher incidence of cerebrovascular and cardiovascular diseases [<xref ref-type="bibr" rid="CR20">20</xref>]. Studies also suggest that the relationship between PD and CVD is complex, with overlapping biological mechanisms, including inflammation, insulin resistance, lipid metabolism and oxidative stress [<xref ref-type="bibr" rid="CR31">31</xref>]. These scientific discoveries corroborate our study's perspective, suggesting that PD increases the likelihood of mortality associated with CVD.</p><p id="Par22">In our stratified analysis, we identified several factors that influence the association between PD and CVD mortality, such as older age, Non-Hispanic White, male, lower BMI, never smoking and past or current alcohol consumption. Similar to a South Korea study that found a negative dose&#8211;response relationship between BMI at diagnosis and mortality in patients with PD, a 10% change in BMI was significantly linked to mortality outcomes [<xref ref-type="bibr" rid="CR18">18</xref>]. One possible explanation for this negative correlation is that higher BMI affects insulin levels, which may play a beneficial role in dopaminergic neurodegeneration [<xref ref-type="bibr" rid="CR32">32</xref>]. We identified a significant interaction regarding CVD mortality among individuals with PD, distinguishing between the male and female subgroups. A retrospective study analysed the trend of PD mortality revealed that males had a mortality rate twice higher than females [<xref ref-type="bibr" rid="CR33">33</xref>]. The gender disparity in PD development could be attributed to the potential neuroprotective effect of female gonadotropins, especially circulating oestradiol, on the dopaminergic system. Men typically acquire PD at a younger age than women, leading to a higher mortality rate in men at an earlier stage, which may counterbalance other risk factors [<xref ref-type="bibr" rid="CR34">34</xref>]. In the United States, racial and ethnic disparities exist in access to neurological care, with black and Hispanic patients being less likely than white patients to consult outpatient neurologists. This discrepancy suggests that white patients have a greater likelihood of being diagnosed with PD [<xref ref-type="bibr" rid="CR35">35</xref>] possibly attributed to their overall higher socioeconomic status in terms of education and income compared with minority populations. Consequently, this disparity may contribute to the higher CVD mortality rates in white individuals with PD in comparison with other racial and ethnic groups. Numerous clinical studies have demonstrated a negative correlation between smoking and the occurrence of PD in both genders [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. Smoking might have a protective effect against Parkinson's disease; however, the cause of the high vulnerability to CVD mortality in patients with PD who have never smoked remains unclear.</p><sec id="Sec13"><title>Study strengths and limitations</title><p id="Par23">This study is the first to examine CVD mortality in patients with PD by using data from the NHANES. The sample size was both large and representative, allowing for a comprehensive analysis. However, this study has some limitations. The determination of PD within our research was reliant on participants&#8217; self-reported medication usage, without corroboration through a formal medical diagnosis. This approach acknowledges the possibility that a subset of participants may be either unaware of their PD status or may exhibit milder symptoms not necessitating pharmacological intervention, potentially leading to an underrepresented sample. Moreover, we are mindful that patients with tremor-associated neurological conditions other than PD might be prescribed antiparkinsonian medications yet lack a definitive PD diagnosis. Such instances could precipitate misclassification within our study, thereby introducing a bias into our research outcomes. To address these limitations, future investigations should endeavour to adopt more rigorous diagnostic methodologies. This might entail comprehensive clinical evaluations by specialists in movement disorders or the employment of standardised diagnostic instruments. By integrating these refined diagnostic practices, the accuracy of PD case identification can be enhanced, thereby mitigating the risk of misclassification.</p></sec></sec><sec id="Sec14"><title>Conclusion</title><p id="Par24">This large cohort study suggests that individuals with PD have a higher risk of CVD mortality compared with those without PD. The association appears to be stronger in older age, non-Hispanic white individuals, males, those with lower BMI, non-smokers and those who currently or previously consumed alcohol. Future research should delve deeper into the biological mechanisms underlying this relationship to develop effective strategies for reducing CVD mortality in individuals with PD.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors thank the NHANES staff, investigators, and participants. We thank Dr Liu Jie (People's Liberation Army of China General Hospital, Beijing, China) for assistance with this revision.</p></ack><notes notes-type="author-contribution"><title>Authors&#8217; contributions</title><p>Li Ke and Lei Zhao wrote the main text of the manuscript, while Wenli Xing prepared the data statistics. Qiaosheng Tang was involved in the data analysis process during the repair. All authors have revised the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work has not received any specific grant from any funding in the public, commercial or not-for-profit sectors.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par25">The NHANES obtained approval from the National Centre for Health Statistics Research Ethics Review Board and was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par26">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par27">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bloem</surname><given-names>BR</given-names></name><etal/></person-group><article-title>Parkinson&#8217;s disease</article-title><source>Lancet</source><year>2021</year><volume>397</volume><issue>10291</issue><fpage>2284</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(21)00218-x</pub-id><pub-id pub-id-type="pmid">33848468</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>T</given-names></name><etal/></person-group><article-title>Disease burden of Parkinson&#8217;s disease in China and its provinces from 1990 to 2021: findings from the global burden of disease study 2021</article-title><source>Lancet Regional Health-Western Pacific</source><year>2024</year><volume>46</volume><fpage>101078</fpage><pub-id pub-id-type="doi">10.1016/j.lanwpc.2024.101078</pub-id><pub-id pub-id-type="pmid">38745974</pub-id><pub-id pub-id-type="pmcid">PMC11091691</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dorsey</surname><given-names>ER</given-names></name><etal/></person-group><article-title>The emerging evidence of the Parkinson pandemic</article-title><source>J Parkinsons Dis</source><year>2018</year><volume>8</volume><issue>s1</issue><fpage>S3</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.3233/jpd-181474</pub-id><pub-id pub-id-type="pmid">30584159</pub-id><pub-id pub-id-type="pmcid">PMC6311367</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moscovich</surname><given-names>M</given-names></name><name name-style="western"><surname>Boschetti</surname><given-names>G</given-names></name><name name-style="western"><surname>Moro</surname><given-names>A</given-names></name><name name-style="western"><surname>Teive</surname><given-names>HAG</given-names></name><name name-style="western"><surname>Hassan</surname><given-names>A</given-names></name><name name-style="western"><surname>Munhoz</surname><given-names>RP</given-names></name></person-group><article-title>Death certificate data and causes of death in patients with parkinsonism</article-title><source>Parkinsonism Relat Disord</source><year>2017</year><volume>41</volume><fpage>99</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2017.05.022</pub-id><pub-id pub-id-type="pmid">28572021</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Korten</surname><given-names>A</given-names></name><etal/></person-group><article-title>Stroke and Idiopathic Parkinson&#8217;s Disease: Does a Shortage of Dopamine Offer Protection against Stroke?</article-title><source>Mov Disord.</source><year>2001</year><volume>16</volume><issue>1</issue><fpage>119</fpage><lpage>23</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1531-8257(200101)16:1&amp;#x0003c;119::aid-mds1024&amp;#x0003e;3.0.co;2-w</pub-id><pub-id pub-id-type="pmid">11215570</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bodenmann</surname><given-names>P</given-names></name><name name-style="western"><surname>Ghika</surname><given-names>J</given-names></name><name name-style="western"><surname>Van Melle</surname><given-names>G</given-names></name><name name-style="western"><surname>Bogousslavsky</surname><given-names>J</given-names></name></person-group><article-title>Comorbidit&#233;s neurologiques du parkinsonisme [Neurological comorbidity in parkinsonism]</article-title><source>Revue neurologique</source><year>2001</year><volume>157</volume><issue>1</issue><fpage>45</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">11240547</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>JH</given-names></name><name name-style="western"><surname>Kim</surname><given-names>DH</given-names></name><name name-style="western"><surname>Park</surname><given-names>YG</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>DY</given-names></name><name name-style="western"><surname>Choi</surname><given-names>M</given-names></name><name name-style="western"><surname>Jung</surname><given-names>JH</given-names></name><name name-style="western"><surname>Han</surname><given-names>K</given-names></name></person-group><article-title>Association of Parkinson disease with risk of cardiovascular disease and all-cause mortality: a nationwide, population-based cohort study</article-title><source>Circulation</source><year>2020</year><volume>141</volume><issue>14</issue><fpage>1205</fpage><lpage>1207</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.119.044948</pub-id><pub-id pub-id-type="pmid">32250706</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heron</surname><given-names>M</given-names></name></person-group><article-title>Deaths: leading causes for 2017</article-title><source>Natl Vital Stat Rep</source><year>2019</year><volume>68</volume><issue>6</issue><fpage>1</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">32501203</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeMarco</surname><given-names>EC</given-names></name><name name-style="western"><surname>Al-Hammadi</surname><given-names>N</given-names></name><name name-style="western"><surname>Hinyard</surname><given-names>L</given-names></name></person-group><article-title>Exploring treatment for depression in Parkinson's patients: a cross-sectional analysis</article-title><source>Int J Environ Res Public Health</source><year>2021</year><volume>18</volume><issue>16</issue><fpage>8596</fpage><pub-id pub-id-type="doi">10.3390/ijerph18168596</pub-id><pub-id pub-id-type="pmid">34444343</pub-id><pub-id pub-id-type="pmcid">PMC8392211</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fox</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Park</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Mischley</surname><given-names>LK</given-names></name></person-group><article-title>Comparison of associations between MIND and Mediterranean diet scores with patient-reported outcomes in Parkinson's disease</article-title><source>Nutrients</source><year>2022</year><volume>14</volume><issue>23</issue><fpage>5185</fpage><pub-id pub-id-type="doi">10.3390/nu14235185</pub-id><pub-id pub-id-type="pmid">36501214</pub-id><pub-id pub-id-type="pmcid">PMC9739738</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Di</surname><given-names>Q</given-names></name></person-group><article-title>Association of dietary patterns with Parkinson's disease: a cross-sectional study based on the United States National Health and Nutritional Examination Survey Database</article-title><source>Eur Neurol</source><year>2023</year><volume>86</volume><issue>1</issue><fpage>63</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1159/000527537</pub-id><pub-id pub-id-type="pmid">36470220</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Hansson</surname><given-names>O</given-names></name><name name-style="western"><surname>Sonestedt</surname><given-names>E</given-names></name><name name-style="western"><surname>Born&#233;</surname><given-names>Y</given-names></name></person-group><article-title>Comparison of risk factors for Parkinson's disease, coronary events and ischemic stroke</article-title><source>NPJ Parkinsons Dis</source><year>2022</year><volume>8</volume><issue>1</issue><fpage>107</fpage><pub-id pub-id-type="doi">10.1038/s41531-022-00374-z</pub-id><pub-id pub-id-type="pmid">36008425</pub-id><pub-id pub-id-type="pmcid">PMC9411547</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Cen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Luo</surname><given-names>X</given-names></name></person-group><article-title>Association between dietary inflammatory index and Parkinson&#8217;s disease from National Health and Nutrition Examination Survey (2003&#8211;2018): a cross-sectional study</article-title><source>Front Neurosci</source><year>2023</year><volume>17</volume><fpage>1203979</fpage><pub-id pub-id-type="doi">10.3389/fnins.2023.1203979</pub-id><pub-id pub-id-type="pmid">37547135</pub-id><pub-id pub-id-type="pmcid">PMC10398569</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Dohrmann SM, Curtin LR. National health and nutrition examination survey: analytic guidelines, 1999-2010. Vital Health Stat 2. 2013;161:1&#8211;24.<pub-id pub-id-type="pmid">25090154</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>W</given-names></name><name name-style="western"><surname>Lin</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Z</given-names></name></person-group><article-title>Association between migraine and cardiovascular disease mortality: a prospective population-based cohort study</article-title><source>Headache</source><year>2023</year><volume>63</volume><issue>8</issue><fpage>1109</fpage><lpage>1118</lpage><pub-id pub-id-type="doi">10.1111/head.14616</pub-id><pub-id pub-id-type="pmid">37655645</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Kuraishy</surname><given-names>HM</given-names></name><name name-style="western"><surname>Fahad</surname><given-names>EH</given-names></name><name name-style="western"><surname>Al-Windy</surname><given-names>S</given-names></name><name name-style="western"><surname>El-Sherbeni</surname><given-names>SA</given-names></name><name name-style="western"><surname>Negm</surname><given-names>WA</given-names></name><name name-style="western"><surname>Batiha</surname><given-names>GE</given-names></name></person-group><article-title>The effects of cholesterol and statins on Parkinson's neuropathology: a narrative review</article-title><source>Inflammopharmacology</source><year>2024</year><volume>32</volume><issue>2</issue><fpage>917</fpage><lpage>925</lpage><pub-id pub-id-type="doi">10.1007/s10787-023-01400-z</pub-id><pub-id pub-id-type="pmid">38499742</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeong</surname><given-names>SM</given-names></name><name name-style="western"><surname>Han</surname><given-names>K</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D</given-names></name><name name-style="western"><surname>Rhee</surname><given-names>SY</given-names></name><name name-style="western"><surname>Jang</surname><given-names>W</given-names></name><name name-style="western"><surname>Shin</surname><given-names>DW</given-names></name></person-group><article-title>Body mass index, diabetes, and the risk of Parkinson&#8217;s disease</article-title><source>Mov Disord</source><year>2020</year><volume>35</volume><issue>2</issue><fpage>236</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1002/mds.27922</pub-id><pub-id pub-id-type="pmid">31785021</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoon</surname><given-names>SY</given-names></name><name name-style="western"><surname>Heo</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Lee</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Shin</surname><given-names>J</given-names></name><name name-style="western"><surname>Kim</surname><given-names>YW</given-names></name><name name-style="western"><surname>Yang</surname><given-names>SN</given-names></name><name name-style="western"><surname>Park</surname><given-names>YG</given-names></name></person-group><article-title>Initial BMI and weight loss over time predict mortality in Parkinson disease</article-title><source>J Am Med Dir Assoc</source><year>2022</year><volume>23</volume><issue>10</issue><fpage>1719.e1</fpage><lpage>1719.e7</lpage><pub-id pub-id-type="doi">10.1016/j.jamda.2022.07.015</pub-id><pub-id pub-id-type="pmid">36007544</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collaboration</surname><given-names>PS</given-names></name><name name-style="western"><surname>Whitlock</surname><given-names>G</given-names></name><name name-style="western"><surname>Lewington</surname><given-names>S</given-names></name><name name-style="western"><surname>Sherliker</surname><given-names>P</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>R</given-names></name><name name-style="western"><surname>Emberson</surname><given-names>J</given-names></name><name name-style="western"><surname>Halsey</surname><given-names>J</given-names></name><name name-style="western"><surname>Qizilbash</surname><given-names>N</given-names></name><name name-style="western"><surname>Collins</surname><given-names>R</given-names></name><name name-style="western"><surname>Peto</surname><given-names>R</given-names></name></person-group><article-title>Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies</article-title><source>Lancet (London, England)</source><year>2009</year><volume>373</volume><issue>9669</issue><fpage>1083</fpage><lpage>1096</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(09)60318-4</pub-id><pub-id pub-id-type="pmid">19299006</pub-id><pub-id pub-id-type="pmcid">PMC2662372</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hughes</surname><given-names>TA</given-names></name><name name-style="western"><surname>Ross</surname><given-names>HF</given-names></name><name name-style="western"><surname>Mindham</surname><given-names>RH</given-names></name><name name-style="western"><surname>Spokes</surname><given-names>EG</given-names></name></person-group><article-title>Mortality in Parkinson's disease and its association with dementia and depression</article-title><source>Acta Neurol Scand</source><year>2004</year><volume>110</volume><issue>2</issue><fpage>118</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0404.2004.00292.x</pub-id><pub-id pub-id-type="pmid">15242420</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hely</surname><given-names>MA</given-names></name><name name-style="western"><surname>Morris</surname><given-names>JG</given-names></name><name name-style="western"><surname>Traficante</surname><given-names>R</given-names></name><name name-style="western"><surname>Reid</surname><given-names>WG</given-names></name><name name-style="western"><surname>O'Sullivan</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>PM</given-names></name></person-group><article-title>The sydney multicentre study of Parkinson's disease: progression and mortality at 10 years</article-title><source>J Neurol Neurosurg Psychiatry</source><year>1999</year><volume>67</volume><issue>3</issue><fpage>300</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1136/jnnp.67.3.300</pub-id><pub-id pub-id-type="pmid">10449550</pub-id><pub-id pub-id-type="pmcid">PMC1736543</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoogland</surname><given-names>J</given-names></name><name name-style="western"><surname>Post</surname><given-names>B</given-names></name><name name-style="western"><surname>de Bie</surname><given-names>RMA</given-names></name></person-group><article-title>Overall and disease related mortality in Parkinson&#8217;s disease - a longitudinal cohort study</article-title><source>J Parkinsons Dis</source><year>2019</year><volume>9</volume><issue>4</issue><fpage>767</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.3233/JPD-191652</pub-id><pub-id pub-id-type="pmid">31498129</pub-id><pub-id pub-id-type="pmcid">PMC6839485</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Gong</surname><given-names>DD</given-names></name><name name-style="western"><surname>Man</surname><given-names>CF</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Y</given-names></name></person-group><article-title>Parkinson's disease and risk of mortality: meta-analysis and systematic review</article-title><source>Acta Neurol Scand</source><year>2014</year><volume>129</volume><issue>2</issue><fpage>71</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1111/ane.12201</pub-id><pub-id pub-id-type="pmid">24256347</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fall</surname><given-names>PA</given-names></name><name name-style="western"><surname>Saleh</surname><given-names>A</given-names></name><name name-style="western"><surname>Fredrickson</surname><given-names>M</given-names></name><name name-style="western"><surname>Olsson</surname><given-names>JE</given-names></name><name name-style="western"><surname>Gran&#233;rus</surname><given-names>AK</given-names></name></person-group><article-title>Survival time, mortality, and cause of death in elderly patients with Parkinson's disease: a 9-year follow-up</article-title><source>Mov Disord</source><year>2003</year><volume>18</volume><issue>11</issue><fpage>1312</fpage><lpage>1316</lpage><pub-id pub-id-type="doi">10.1002/mds.10537</pub-id><pub-id pub-id-type="pmid">14639673</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Struck</surname><given-names>LK</given-names></name><name name-style="western"><surname>Rodnitzky</surname><given-names>RL</given-names></name><name name-style="western"><surname>Dobson</surname><given-names>JK</given-names></name></person-group><article-title>Stroke and its modification in Parkinson's disease</article-title><source>Stroke</source><year>1990</year><volume>21</volume><issue>10</issue><fpage>1395</fpage><lpage>1399</lpage><pub-id pub-id-type="doi">10.1161/01.STR.21.10.1395</pub-id><pub-id pub-id-type="pmid">2219202</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nataraj</surname><given-names>A</given-names></name><name name-style="western"><surname>Rajput</surname><given-names>AH</given-names></name></person-group><article-title>Parkinson's disease, stroke, and related epidemiology</article-title><source>Mov Disord</source><year>2005</year><volume>20</volume><issue>11</issue><fpage>1476</fpage><lpage>1480</lpage><pub-id pub-id-type="doi">10.1002/mds.20608</pub-id><pub-id pub-id-type="pmid">16037918</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piqueras-Flores</surname><given-names>J</given-names></name><name name-style="western"><surname>L&#243;pez-Garc&#237;a</surname><given-names>A</given-names></name><name name-style="western"><surname>Moreno-Reig</surname><given-names>&#193;</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Mart&#237;nez</surname><given-names>A</given-names></name><name name-style="western"><surname>Hern&#225;ndez-Gonz&#225;lez</surname><given-names>A</given-names></name><name name-style="western"><surname>Vaamonde-Gamo</surname><given-names>J</given-names></name><name name-style="western"><surname>Jurado-Rom&#225;n</surname><given-names>A</given-names></name></person-group><article-title>Structural and functional alterations of the heart in Parkinson's disease</article-title><source>Neurol Res</source><year>2018</year><volume>40</volume><issue>1</issue><fpage>53</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1080/01616412.2017.1390933</pub-id><pub-id pub-id-type="pmid">29057715</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kinbara</surname><given-names>T</given-names></name><name name-style="western"><surname>Hayano</surname><given-names>T</given-names></name><name name-style="western"><surname>Otani</surname><given-names>N</given-names></name><name name-style="western"><surname>Furutani</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>S</given-names></name></person-group><article-title>Iodine-123 metaiodobenzylguanidine imaging can predict future cardiac events in Japanese patients with Parkinson's disease</article-title><source>Ann Nucl Med</source><year>2013</year><volume>27</volume><issue>2</issue><fpage>123</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1007/s12149-012-0662-8</pub-id><pub-id pub-id-type="pmid">23086545</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Madias</surname><given-names>JE</given-names></name></person-group><article-title>Entacapone, Parkinson&#8217;s disease, &#8220;functional adrenergic denervation&#8221;, and Takotsubo syndrome</article-title><source>Parkinsonism Relat Disord</source><year>2015</year><volume>21</volume><issue>4</issue><fpage>426</fpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2014.11.011</pub-id><pub-id pub-id-type="pmid">25443553</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwanaga</surname><given-names>K</given-names></name><name name-style="western"><surname>Wakabayashi</surname><given-names>K</given-names></name><name name-style="western"><surname>Yoshimoto</surname><given-names>M</given-names></name><name name-style="western"><surname>Tomita</surname><given-names>I</given-names></name><name name-style="western"><surname>Satoh</surname><given-names>H</given-names></name><name name-style="western"><surname>Takashima</surname><given-names>H</given-names></name><name name-style="western"><surname>Satoh</surname><given-names>A</given-names></name><name name-style="western"><surname>Seto</surname><given-names>M</given-names></name><name name-style="western"><surname>Tsujihata</surname><given-names>M</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>H</given-names></name></person-group><article-title>Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body diseases</article-title><source>Neurology</source><year>1999</year><volume>52</volume><issue>6</issue><fpage>1269</fpage><lpage>1271</lpage><pub-id pub-id-type="doi">10.1212/WNL.52.6.1269</pub-id><pub-id pub-id-type="pmid">10214756</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Potashkin</surname><given-names>J</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X</given-names></name><name name-style="western"><surname>Becker</surname><given-names>C</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><name name-style="western"><surname>Foltynie</surname><given-names>T</given-names></name><name name-style="western"><surname>Marras</surname><given-names>C</given-names></name></person-group><article-title>Understanding the links between cardiovascular disease and Parkinson's disease</article-title><source>Mov Disord</source><year>2020</year><volume>35</volume><issue>1</issue><fpage>55</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1002/mds.27836</pub-id><pub-id pub-id-type="pmid">31483535</pub-id><pub-id pub-id-type="pmcid">PMC6981000</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Craft</surname><given-names>S</given-names></name><name name-style="western"><surname>Watson</surname><given-names>GS</given-names></name></person-group><article-title>Insulin and neurodegenerative disease: shared and specific mechanisms</article-title><source>Lancet Neurol</source><year>2004</year><volume>3</volume><issue>3</issue><fpage>169</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(04)00681-7</pub-id><pub-id pub-id-type="pmid">14980532</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rong</surname><given-names>S</given-names></name><name name-style="western"><surname>Xu</surname><given-names>G</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name><name name-style="western"><surname>Snetselaar</surname><given-names>LG</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>RB</given-names></name><name name-style="western"><surname>Li</surname><given-names>B</given-names></name><name name-style="western"><surname>Liao</surname><given-names>J</given-names></name><name name-style="western"><surname>Bao</surname><given-names>W</given-names></name></person-group><article-title>Trends in mortality from Parkinson disease in the United States, 1999&#8211;2019</article-title><source>Neurology</source><year>2021</year><volume>97</volume><issue>20</issue><fpage>e1986</fpage><lpage>e1993</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000012826</pub-id><pub-id pub-id-type="pmid">34706971</pub-id></element-citation></ref><ref id="CR34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cerri</surname><given-names>S</given-names></name><etal/></person-group><article-title>Parkinson&#8217;s disease in women and men: what&#8217;s the difference?</article-title><source>J Parkinson's Dise</source><year>2019</year><volume>9</volume><issue>3</issue><fpage>501</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.3233/JPD-191683</pub-id><pub-id pub-id-type="pmcid">PMC6700650</pub-id><pub-id pub-id-type="pmid">31282427</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saadi</surname><given-names>A</given-names></name><name name-style="western"><surname>Himmelstein</surname><given-names>DU</given-names></name><name name-style="western"><surname>Woolhandler</surname><given-names>S</given-names></name><name name-style="western"><surname>Mejia</surname><given-names>NI</given-names></name></person-group><article-title>Racial disparities in neurologic health care access and utilization in the United States</article-title><source>Neurology</source><year>2017</year><volume>88</volume><issue>24</issue><fpage>2268</fpage><lpage>2275</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000004025</pub-id><pub-id pub-id-type="pmid">28515272</pub-id><pub-id pub-id-type="pmcid">PMC5567325</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hern&#225;n</surname><given-names>MA</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>SM</given-names></name><name name-style="western"><surname>Rueda-deCastro</surname><given-names>AM</given-names></name><name name-style="western"><surname>Colditz</surname><given-names>GA</given-names></name><name name-style="western"><surname>Speizer</surname><given-names>FE</given-names></name><name name-style="western"><surname>Ascherio</surname><given-names>A</given-names></name></person-group><article-title>Cigarette smoking and the incidence of Parkinson's disease in two prospective studies</article-title><source>Ann Neurol</source><year>2001</year><volume>50</volume><issue>6</issue><fpage>780</fpage><lpage>786</lpage><pub-id pub-id-type="doi">10.1002/ana.10028</pub-id><pub-id pub-id-type="pmid">11761476</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gallo</surname><given-names>V</given-names></name><name name-style="western"><surname>Vineis</surname><given-names>P</given-names></name><name name-style="western"><surname>Cancellieri</surname><given-names>M</given-names></name><name name-style="western"><surname>Chiodini</surname><given-names>P</given-names></name><name name-style="western"><surname>Barker</surname><given-names>RA</given-names></name><name name-style="western"><surname>Brayne</surname><given-names>C</given-names></name><name name-style="western"><surname>Pearce</surname><given-names>N</given-names></name><name name-style="western"><surname>Vermeulen</surname><given-names>R</given-names></name><name name-style="western"><surname>Panico</surname><given-names>S</given-names></name><name name-style="western"><surname>Bueno-de-Mesquita</surname><given-names>B</given-names></name><name name-style="western"><surname>Vanacore</surname><given-names>N</given-names></name><name name-style="western"><surname>Forsgren</surname><given-names>L</given-names></name><name name-style="western"><surname>Ramat</surname><given-names>S</given-names></name><name name-style="western"><surname>Ardanaz</surname><given-names>E</given-names></name><name name-style="western"><surname>Arriola</surname><given-names>L</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>J</given-names></name><name name-style="western"><surname>Hansson</surname><given-names>O</given-names></name><name name-style="western"><surname>Gavrila</surname><given-names>D</given-names></name><name name-style="western"><surname>Sacerdote</surname><given-names>C</given-names></name><name name-style="western"><surname>Sieri</surname><given-names>S</given-names></name><name name-style="western"><surname>K&#252;hn</surname><given-names>T</given-names></name><name name-style="western"><surname>Katzke</surname><given-names>VA</given-names></name><name name-style="western"><surname>van der Schouw</surname><given-names>YT</given-names></name><name name-style="western"><surname>Kyrozis</surname><given-names>A</given-names></name><name name-style="western"><surname>Masala</surname><given-names>G</given-names></name><name name-style="western"><surname>Mattiello</surname><given-names>A</given-names></name><name name-style="western"><surname>Perneczky</surname><given-names>R</given-names></name><name name-style="western"><surname>Middleton</surname><given-names>L</given-names></name><name name-style="western"><surname>Saracci</surname><given-names>R</given-names></name><name name-style="western"><surname>Riboli</surname><given-names>E</given-names></name></person-group><article-title>Exploring causality of the association between smoking and Parkinson's disease</article-title><source>Int J Epidemiol</source><year>2019</year><volume>48</volume><issue>3</issue><fpage>912</fpage><lpage>925</lpage><pub-id pub-id-type="doi">10.1093/ije/dyy230</pub-id><pub-id pub-id-type="pmid">30462234</pub-id><pub-id pub-id-type="pmcid">PMC6659366</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>